Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for some breast cancers: Trial

medicalxpress - Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy as the first treatment af…

AI Summary: Trial results indicate that patients with HR‑positive, HER2‑negative advanced breast cancers treated with sacituzumab govitecan‑hziy experienced similar progression‑free survival to those receiving standard care. Two reports from the same trial underlined these findings, reinforcing the therapy’s potential for endocrine therapy‑refractory tumors.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Tucatinib Combination Delays Disease Progression in HER2‑Positive Metastatic Breast Cancer / 5 months

Apixaban linked to lower bleeding than rivaroxaban in head‑to‑head study / 2 months

Sanofi ousts Paul Hudson as Belén Garijo named incoming CEO / 3 months

Zoliflodacin shows promise as single-dose treatment for gonorrhea / 5 months

PAXG regimen shows superior event‐free survival in early pancreatic cancer / 6 months

First-in-human trial primes immune system to accept donor livers / 6 wks

Experimental therapy significantly reduces Parkinson’s toxic protein in early trial / 7 wks